Muscular Dystrophy Association Awards $120,000 to Catabasis Pharmaceuticals, Inc.

Published: Apr 04, 2012

TUCSON, Ariz., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Muscular Dystrophy Association announced today that it has awarded $120,000 to Cambridge, Mass.-based Catabasis Pharmaceuticals as part of a strategic partnership under which the biopharmaceutical company will test two compounds called CAT-1004 and CAT-1040 in the mdx research mouse model of Duchenne muscular dystrophy (DMD).

Back to news